Vistagen Therapeutics Inc

Vistagen Therapeutics Inc operates with a highly liquid capital structure, as evidenced by its cash and equivalents of $119.17 million, which significantly exceeds its total liabilities of $9.37 million, resulting in a current ratio of 23.55. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative leverage profile. The price-to-book ratio of 0.23 and price-to-tangible-book ratio of 0.23 suggest that the company is trading at a substantial discount to its book value, which may reflect market skepticism about its earnings potential or asset quality.

Profitability metrics for Vistagen are negative, with a return on equity (ROE) of -8.33% and a return on assets (ROA) of -7.7%. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets to generate profit. The net income of -$9.52 million and operating income of -$11.36 million further underscore the company's unprofitable operations. The company's operating cash flow of -$25.81 million and free cash flow of -$9.52 million highlight the cash outflows associated with its operations, which are not being offset by revenue generation.

Vistagen's revenue of $197.30 million is derived from a single business segment, with no disclosed geographic breakdown. The absence of segment or geographic diversification increases the company's exposure to market-specific risks, such as regulatory changes or shifts in demand for its products. The company's revenue concentration in a single segment suggests a lack of diversification, which could be a concern for investors seeking to mitigate risk.

The company's growth trajectory is constrained by its current financial performance. The outlook for the current fiscal year does not indicate any significant revenue growth, and the absence of positive earnings trends suggests that the company is not on a path to profitability. The company's operating losses and negative cash flows indicate that it is not currently generating the financial returns necessary to support growth initiatives.

Risk factors for Vistagen include its unprofitable operations and negative cash flows, which could lead to liquidity constraints if the company is unable to secure additional financing. The company's dilution potential is currently low, as there are no immediate filing-based liquidity or dilution flags. However, the company's reliance on cash reserves to fund operations could necessitate future equity or debt financing, which may result in dilution for existing shareholders.

Recent events for Vistagen include the disclosure of its financial results, which show continued operating losses and negative cash flows. The company has not issued any new products or received regulatory approvals that would significantly impact its revenue. The absence of recent positive developments suggests that the company is not currently in a position to capitalize on market opportunities.

Analysts project 1,484% upside to a mean price target of $3.73, significantly above the current market price of $0.24.

The company maintains a low debt-to-equity ratio of 0.37, indicating a conservative capital structure with minimal leverage risk.

Vistagen exhibits best-in-class cash conversion metrics relative to its biotechnology cohort, suggesting efficient capital management despite losses.

The firm holds a strong current ratio of 3.67, providing ample liquidity to cover short-term obligations without immediate distress.

Net losses widened to $51.4 million in FY2025, reflecting deteriorating profitability and an inability to generate positive earnings.

Operating margin of -57.57% places the company in the bottom quartile of its biotechnology cohort, indicating poor operational efficiency.

Free cash flow deteriorated to -$51.5 million in FY2025, highlighting significant cash burn and reliance on external financing.

The company faces high credit risk, which may increase borrowing costs and limit access to necessary capital markets.

Revenue $303.0k, +29,5% YoY; Operating income −29,3% YoY.

• ▍Revenue $303.0k, +29,5% YoY
• ▍Operating income −29,3% YoY
• ▍Net income −34,1% YoY
• ▍Free cash flow −34,3% YoY
• ▍Net margin -6237.3%

Revenue $258.0k, +41,0% YoY; Operating income −41,0% YoY.

• ▍Revenue $258.0k, +41,0% YoY
• ▍Operating income −41,0% YoY
• ▍Net income −49,8% YoY
• ▍Free cash flow −49,6% YoY
• ▍Net margin -7526.0%

Revenue $244.0k, +190,5% YoY; Operating income −30,3% YoY.

• ▍Revenue $244.0k, +190,5% YoY
• ▍Operating income −30,3% YoY
• ▍Net income −40,6% YoY
• ▍Free cash flow −40,8% YoY
• ▍Net margin -6186.5%

Operating income −27,6% YoY; Net income −43,2% YoY.

• ▍Operating income −27,6% YoY
• ▍Net income −43,2% YoY
• ▍Free cash flow −43,8% YoY

Revenue $234.0k; Operating income -$15.1M.

• ▍Revenue $234.0k
• ▍Operating income -$15.1M
• ▍Net margin -6020.9%

Revenue $183.0k; Operating income -$14.2M.

• ▍Revenue $183.0k
• ▍Operating income -$14.2M
• ▍Net margin -7082.5%

Revenue $84.0k; Operating income -$12.1M.

• ▍Revenue $84.0k
• ▍Operating income -$12.1M
• ▍Net margin -12777.4%

Revenue $197.3k; Operating income -$11.4M.

• ▍Revenue $197.3k
• ▍Operating income -$11.4M
• ▍Net margin -4825.8%

Revenue $486.0k, −54,3% YoY; Operating income −69,5% YoY.

• ▍Revenue $486.0k, −54,3% YoY
• ▍Operating income −69,5% YoY
• ▍Net income −75,1% YoY
• ▍Free cash flow −75,7% YoY
• ▍Net margin -10579.8%

Revenue $1.1M, +568,1% YoY; Operating income +44,3% YoY.

• ▍Revenue $1.1M, +568,1% YoY
• ▍Operating income +44,3% YoY
• ▍Net income +50,4% YoY
• ▍Free cash flow +50,6% YoY
• ▍Net margin -2759.6%

Revenue $1.1M, +1,8% YoY; Operating income −166,4% YoY.

• ▍Revenue $1.1M, +1,8% YoY
• ▍Operating income −166,4% YoY
• ▍Net income −166,3% YoY
• ▍Free cash flow −14,8% YoY
• ▍Net margin -4307.2%

Revenue $1.1M; Operating income -$17.9M.

• ▍Revenue $1.1M
• ▍Operating income -$17.9M
• ▍Net margin -1646.1%